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Abstract
Background: Interleukin (IL) 11 is produced by human endometrium and endometrial cancer tissue. It has roles in 
endometrial epithelial cell adhesion and trophoblast cell invasion, two important processes in cancer progression. This 
study aimed to determine the levels of IL11 in uterine lavage fluid in women with endometrial cancer and 
postmenopausal women. It further aimed to determine the levels of IL11 protein and its signaling molecules in human 
endometrial cancer of varying grades, and endometrium from postmenopausal women and IL11 signalling 
mechanisms in endometrial cancer cell lines.
Methods: IL11 levels in uterine lavage were measured by ELISA. IL11, IL11 receptor(R) α, phosphorylated (p) STAT3 and 
SOCS3 were examined by immunohistochemistry in endometrial carcinomas and in control endometrium from 
postmenopausal women and normal cycling women. The effect of IL11 on pSTAT3/STAT3 and SOCS3 protein 
abundance in endometrial cancer cell lines and non-cancer endometrial epithelial cells was determined by Western 
blot.
Results: IL11 was present in uterine flushings and was significantly higher in women with Grade 1 carcinomas 
compared to postmenopausal women (p < 0.05). IL11 immunostaining was significantly elevated in the endometrial 
tumour epithelial cells from Grade 1 and 3 compared to endometrial epithelium from postmenopausal and cycling 
women. IL11Rα immunostaining intensity was increased in cancer epithelium in the Grades 1 and 2 tumours 
compared to epithelium from postmenopausal women. Both IL11 and IL11Rα localized to vascular endothelial and 
smooth muscle cells while IL11 also localized to subsets of leucocytes in the cancer tissues. pSTAT3 was found in both 
the tumour epithelial and stromal compartments but was maximal in the tumour epithelial cells, while SOCS3 was 
predominantly found in the tumour epithelial cells. pSTAT3 staining intensity was significantly higher in Grade 1 and 2 
tumour epithelial cells compared to epithelial cells from cycling and postmenopausal women. SOCS3 staining intensity 
did not differ between between each tumour and postmenopausal endometrial epithelium but SOCS3 in cycling 
endometrium was significantly higher compared to postmonopausal and Tumour Grades 2 and 3. IL11 increased 
pSTAT3/STAT3 in all tumour cell lines, while SOCS3 abundance was increased only in one tumour cell line.
Conclusions: The present study suggests that IL11 in uterine washings may be useful as a diagnostic marker for early 
stage endometrial cancer. It indicates that IL11, along with its specific receptor, IL11Rα, and downstream signalling 
molecules, STAT3 and SOCS3, are likely to play a role in the progression of endometrial carcinoma. The precise role of 
IL11 in endometrial cancer remains to be elucidated.
Background
Endometrial cancer is the most common gynaecological
malignancy [1]. Since it typically affects postmenopausal
women, a significantly increased risk occurs in women
from age 40 and thus endometrial cancer is increasingly
frequent in many advanced countries [1]. The invasion of
endometrial cancer cells through the myometrium and
their migration to the nearby lymph nodes are key factors
related to its poor prognosis [2]. Despite a relatively high
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incidence of uterine cancer, particularly in postmeno-
pausal women, a suitable screening test is not available
[3]. Additionally, despite advances in the treatment of
endometrial cancer, the increasing death rate associated
with the disease is increasing demonstrating new treat-
ments are required [4]. Endometrial cancer or adenocar-
cinoma (type 1), which accounts for about 90% of
endometrial cancers, begins in the glandular epithelial
cells of the endometrium. Factors that influence endome-
trial epithelial cell function and are upregulated early in
the disease may therefore prove to be critical potential
diagnostic and therapeutic targets.
Interleukin (IL) 11 belongs to the IL6 family of cytok-
ines and signals via a heterodimeric complex of IL11
receptor (R) α and gp130. The cellular responses of IL11
are induced by the activation of downstream Janus
kinases (JAK) that phosphorylate the latent cytoplasmic
transcription factors, signal transducer and activator of
transcription (STAT) [5]. Phosphorylated (p) or activated
STAT proteins translocate to the nucleus to modulate
gene transcription [6]. Cytokine signalling is tightly regu-
lated by a variety of mechanisms [7]. The inducible sup-
pressor of cytokine signalling (SOCS) proteins, a family
with 8 members (SOCS1-SOCS7 and CIS), are expressed
in response to cytokine stimulation of STAT phosphory-
lation acting in a negative feedback mechanism to hinder
the activities of cytokine receptors [8,9]. IL11 signals via
pSTAT3 in human endometrial epithelial cells [10,11] and
stimulates SOCS3 in human endometrial cells [9]. IL11 is
expressed by endometrial glandular epithelium in women
during the menstrual cycle [12]. A recent study had iden-
tified that IL11 and IL11Rα are expressed in endometrial
cancer [13], although there are no studies comparing the
levels of IL11 protein in endometrial cancer and post-
menopausal women in whom the vast majority of endo-
metrial cancers develop. It is also not knownswhether
IL11 downstream signalling is active in endometrial can-
cer, which would suggest a role for IL11 in carcinogene-
sis.
Numerous studies have suggested that IL11 has roles in
human gastric, prostate and bone cancer [14-17]. In addi-
tion critical roles for pSTAT3 and SOCS3 in cancer have
also been proposed [8,18,19]. Tumor cell survival
depends on the cells' ability to adhere to, migrate and
invade through the tissue and to metastasize into other
organs and tissues [20]. We recently showed that IL11
regulates human endometrial epithelial cell adhesion and
the migration and invasion of human trophoblast cells
[10,21,22]. It has also been suggested that factors present
in uterine lavage fluid correlate with the presence of
endometrial cancer [23].
In the current study, we determined the levels of IL11
in uterine lavage in women with endometrial cancer and
postmenopausal controls. We compared IL11, IL11Rα,
pSTAT3 and SOCS3 protein in human endometrial carci-
nomas of varying histologic grades with endometrium
from postmenopausal and cycling women. We deter-
mined the effect of IL11 on its downstream signaling
molecules in endometrial cancer and non-cancer endo-
metrial epithelial cells.
Methods
Patients and tissues
Endometrial cancer tissue biopsies (N = 16) were col-
lected from postmenopausal women undergoing total
abdominal hysterectomy for endometrial carcinoma at
the Monash Medical Centre Melbourne, Australia. The
Human Ethics Committee approved the research project
and informed consent was obtained from each patient
participating in this study. Details of individual patients
are provided in Table 1. All tissues were examined and
tumors were graded histologically by a specialist gyneco-
logical pathologist according to the guidelines of the
International Federation of Gynecology and Obstetrics
(FIGO, 1998). In this system the presence of vascular/
lymphatic invasion was noted and the depth of myome-
trial invasion was classified as either: no invasion, < 50%
myometrial invasion or > 50% myometrial invasion. Biop-
sies of endometrium were also obtained from postmeno-
pausal women (N = 4) undergoing minor gynaecological
procedures unrelated to endometrial pathology. Histo-
logical examination by a specialist gynecological patholo-
gist confirmed whether the endometrium from post-
menopausal women was atrophic or active. A large
majority of endometrium collected from postmenopausal
women are atrophic as they are no longer under hor-
monal control so that with very little endometrium is
present, thus we were very limited in the number of tissue
samples of 'active' endometrium we could include in this
study. We therefore also collected endometrium from
proliferative phase endometrium (N = 10) as a second
group of non-tumour normal controls. The control pro-
liferative endometrial biopsies were collected at curettage
from women between day 7 and 13 of their menstrual
cycle that were scheduled for tubal ligation or were
undergoing testing for tubal patency. Tissues were
assessed by a pathologist and had no obvious endometrial
pathology. The women had no steroid treatment or other
medication for at least 2-3 months before the collection
of tissue. Written informed consent was obtained from
each patient and the study was approved by the Southern
Health Human Research and Ethics committee. All endo-
metrial biopsies were fixed overnight in 4% neutral buff-
ered formalin, prior to routine paraffin embedding.
Features of patients
For immunohistochemistry studies: There were 16 can-
cer patients, with an age range of 34-88 years (mean age =Yap et al. Reproductive Biology and Endocrinology 2010, 8:63
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64.4 years with standard deviation = 14.1) (Table 1), while
the postmenopausal women had an age range of 51-60
years with a mean age of 54.4 years and a standard devia-
tion of 4.0. Normal cycling women were aged between
(29-41). All four of the postmenopausal women had
"active" endometrium. Five or six biopsies were collected
from each histologic Grades 1, 2 and 3 carcinomas. All
patients were diagnosed with endometrioid adenocarci-
noma tumors. Myometrial invasion was present in 85.7%
of patients; of these, 66.7% had invasion to less than 50%
of the myometrium, and 33.3% had invasion to 50% or
more of the myometrium (Table 1). The presence of vas-
cular/lymphatic invasion, as assessed by tumor histopa-
t h o l o g y ,  w a s  a p p a r e n t  i n  5 6 %  o f  p a t i e n t s  ( d a t a  n o t
shown).
Uterine lavage were collected from a subgroup of the
women with endometrial carcinoma (Grade 1 N = 4,
Grade 2 N = 5, Grade 3 N = 6; mean age = 69.3 years with
standard deviation = 12.9) and postmenopausal controls
(N = 4, mean age = 73.7 and a standard deviation of 11.1).
IL11 in uterine fluid
Uterine lavages (uterine washings) were collected from
postmenopausal women (N = 4) and women with endo-
metrial cancer above except for women with Grade 1 car-
cinoma where washings were collected from 4 women
instead of 5 women (Grade 1-3 (N = 4; 5; 6 respectively)
as previously described [24]. Uterine fluid from all
women was concentrated 3-4 fold using Nanosep micro-
concentration devices with a 3 K cut-off (Pall Life Sci-
ences, East Hills, NY). IL11 was then measured in the
samples by ELISA as previously described [25].
IL-11 and IL-11Rα immunohistochemistry
Immunohistochemistry for IL11 and IL11Rα was per-
formed as described previously [25] using a monoclonal
anti-huIL-11 (5E3) and antihuIL-11Rα (4D12) antibodies
(generous gifts from Dr. Lorraine Robb). Briefly, paraffin
sections (5 μm) were dewaxed in histosol and rehydrated
i n  a  g r a d e d  s e r i e s  o f  e t h a n o l .  E n d o g e n o u s  p e r o x i d a s e
activity was quenched by immersion in 3% H2O2 in meth-
anol for 10 min. Non-specific staining was blocked using
a blocking solution of 10% normal horse serum (Sigma-
Aldrich Inc., Missouri, USA) and 2% normal human
serum, diluted in 1× Tris-buffered saline (TBS) for 30
min. Primary antibodies were diluted to 4 μg/ml in block-
ing solution and applied for 18 h at 4°C. A non-immune
isotype IgG negative control (R&D Systems Inc., Minne-
apolis, MN, USA) diluted to a matching concentration as
the primary antibody, was also included for each tissue.
Antibody localisation was detected by sequential applica-
tion of biotinylated horse anti-mouse IgG (Vector Labo-
ratories, Burlingame, CA, USA) diluted 1:200 in blocking
solution for 30 min and an avidin-biotin complex conju-
gated to HRP (Vectastain ABC Elite kit; Vector Laborato-
ries, Burlingame, CA, USA). The substrate used was
diaminobenzidine (DAB) (Zymed, San Francisco, USA)
forming an insoluble brown precipitate. Sections were
Table 1: Clinical characteristics of the patients used in this study
Patient no. Age Menopausal status Cancer Grade %MI
16 5 P o s t 1 0
25 6 P o s t 12 9
38 4 P o s t 18 0
43 4 U K1 0
57 8 P o s t 1 4
67 3 P o s t 23 8
75 2 U K2U K
86 0 P o s t 21 8
98 8 P o s t 27 3
10 63 Post 2 100
11 54 Post 3 38
12 59 Post 3 33
13 77 Post 3 25
14 UK UK 3 UK
15 68 Post 3 13
16 55 UK 3 77
Post: post-menopausal; UK: unknown; % MI: % myometrial invasion.Yap et al. Reproductive Biology and Endocrinology 2010, 8:63
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then counterstained in Harris hematoxylin (Sigma Diag-
nostics, St. Louis, USA). Sections from normal endome-
trium were used as positive controls and included in each
immunostaining run to provide quality control.
pSTAT3 and SOCS3 immunohistochemistry
Immunohistochemistry for pSTAT3 and SOCS3 was con-
ducted using polyclonal rabbit anti-mouse (Cell Signal-
ling Technology Inc., MA, USA) and monoclonal rabbit
anti-human (Clone C204) (Immuno-Biological Laborato-
ries Inc., MN, USA) antibodies respectively as previously
shown [9], at final concentration of 0.09 μg/ml and 1 μg/
ml respectively.
Formalin fixed sections were deparaffinized in histosol
and rehydrated in a graded series of ethanol. Endogenous
activity was blocked by incubation in 3% H2O2 in metha-
nol for 10 min. Non-specific staining was blocked using
blocking solutions consisting of 10% normal swine serum
(in-house) and 2% normal human serum for pSTAT3 and
10% normal goat serum (Vector Laboratories) and 2%
normal human serum for SOCS3, each diluted in 1×TBS
for 30 min. Primary antibodies were diluted in the appro-
priate blocking solution and applied for 18 h at 4°C. A
non-immune isotype IgG negative control (R&D Sys-
tems) diluted to a matching concentration as the primary
antibody, was also included for each tissue. Antibody
localisation was detected by sequential application of
biotinylated swine anti rabbit IgG (DAKO, Glostrup,
Denmark) or biotinylated goat anti-rabbit IgG (Vector
Laboratories) diluted 1:200 in blocking solution corre-
spondingly for 30 min and an avidin-biotin complex con-
jugated to HRP (Vectastain ABC Elite kit, Vector
Laboratories). The substrate used was diaminobenzidine
(DAB) (Zymed), which forms an insoluble brown precipi-
tate. Sections were then counterstained in Harris hema-
toxylin (Sigma Diagnostics). Sections from normal pre-
menopausal endometrium were used as positive controls
and included in each immunostaining run to provide
quality control.
Endometrial epithelial cancer and non-cancer cell lines
The endometrial carcinoma cells ECC-1, HEC-1A and
Ishikawa cells were cultured in DMEM/F12 (1:1),
McCoy's 5A and DMEM (Invitrogen, Victoria, Australia)
respectively supplemented with 10% fetal calf serum
(SAFC Biosciences, Victoria, Australia), 1% L-glutamine
(Sigma-Aldrich Pty. Ltd) and 1% antibiotic-antimycotic
(Invitrogen, Victoria, Australia). The non-cancer human
endometrial epithelial (HES) cell line [26] was obtained
from Dr. Douglas Kniss (Ohio State University, Colum-
bus, OH). Cells were maintained in RPMI 1640 (Sigma-
Aldrich Pty. Ltd) supplemented with 10% FCS, 1% L-glu-
tamine and 1% antibiotic- antimycotic. Confluent cells
were transferred into serum free medium for 24 hours
prior to treatment
IL11 regulation of pSTAT3 and SOCS3 in human 
endometrial cancer cell lines
The endometrial cancer cell lines ECC-1, HEC-1A and
Ishikawa and or HES cells were treated with diluents con-
trol, IL11 (1, 10, 100, 500 ng/ml) for 15 minutes or 4
hours. Phosphorylated STAT3 and total STAT3 abun-
dance (15 min) and SOCS3 protein abundance (4 hours;
treatment time was determined from previous studies in
endometrial cells) were analysed by Western blot as pre-
viously described [9] and briefly as follows. Cells were
grown to confluence, the medium aspirated and cells
washed with ice-cold sterile PBS, twice on ice. Cells were
lysed and scraped in ice-cold lysis buffer containing 50
mM Tris Base, 150 mM NaCl, 2 mM EDTA, 2 mM
EGTA, 25 mM NaF, 25 mM β-glycerolphosphate, pH 7.5
and 2 μl/well protease inhibitors cocktail set III (AEBSF,
HCl 100 mM, aprotinin 80 μM, bestatin 5 μM, E-64 1.5
mM, leupeptin hemisulfate 2 mM, pepstatin A 1 mM
(Calbiochem, San Diego, CA, USA). Cell extracts were
then centrifuged at 12000 rpm for 30 min at 4°C, and
supernatant protein quantified using the BCA protein
assay kit (Pierce, Rockford, IL, USA). Equal amounts of
total protein were then resolved on SDS-PAGE gels and
transferred to nitrocellulose membranes. All membranes
were incubated with Ponceau S (Sigma) to ensure equal
protein loading in all lanes. The membranes were blocked
with 5% nonfat dry milk in Tris-buffered saline with 0.1%
Tween (TBST) and probed separately with antibodies
specific for phosphorylated STAT3 (Tyr705, Cell Signal-
ing Technology Inc.) (1:1000), total STAT3 (Cell Signaling
Technology), (1:1000) or SOCS3 (IBL Co. LTD, Gunma,
Japan). The membranes were washed in TBST then incu-
bated for 1 h with horseradish peroxidase (HRP)-conju-
gated rabbit secondary antibody (Dako Cytomation,
Glostrup, Denmark) (1:1500). Finally, the HRP activity
was detected using enhanced chemilluminescence
reagent (Pierce, Rockford, IL, USA). To determine the
specificity of IL-11 in the cells a specific IL11 antagonist
was used (provided by Commonwealth serum Laborato-
ries, Melbourne, Australia) [27].
All in vitro cell culture experiments were performed in
two independent experiments in duplicate.
Semiquantitative analysis of immunostaining and 
statistical analysis
Positive staining was scored semiquantitatively by two
independent observers, blind to the identity of the tissue,
with an intensity score assigned as 0 (negative) to 3 (max-
imal staining intensity). All statistical analyses were per-
formed using GraphPad Prism. Data was analysed by theYap et al. Reproductive Biology and Endocrinology 2010, 8:63
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non-parametric Kruskal-Wallis test followed by the
Dunn's post-hoc test. Differences were considered signifi-
cant at P < 0.05.
Results
IL11 is upregulated in uterine fluid of women with 
endometrial cancer
IL11 was detectable in 3 of 4 postmenopausal controls
and in all the flushings from the Grade 1-3 tumours (Fig
1). IL11 levels in uterine flushings from women with
Grade 1 cancers were higher than that of postmenopausal
control women (p < 0.05) (Fig 1). Uterine flushings from
proliferative phase control women ranged from very low
to undetectable IL11 and were therefore not included in
the results and data analysis. Similarly, an additional
three uterine washings from postmenopausal women
were assayed for IL11 but had undetectable IL11 and
were not included in the data analysis. Overall, IL11 lev-
els in uterine flushings in the cancer patients were higher
than the postmenopausal controls although this did not
reach significance (Fig 1). There was a sub-group of
women with Grade 3 cancers that had very high levels of
IL11 in the uterine flushings (Fig 1).
Immunolocalisation of IL11 and its specific receptor, IL11Rα 
in endometrial cancer and endometrium from post-
menopausal women
Positive immunostaining for IL11 was detected in all can-
cer tissues examined; meanwhile IL11Rα staining was
present in all cancer tissues except two from grade 3 (Fig
2A and 2B). In all tissues, IL11 and IL11Rα immunoreac-
tivity was mainly localised to epithelial cells of tumour
origin (Fig 3A-C and 4A-C respectively). Very little
immunoreactive IL11 and IL11Rα was seen in the stromal
compartment of the tumours (Fig 3A-C and 4A-C respec-
tively). By contrast, only low levels of IL11 and IL11Rα
staining was evident in epithelial cells while stromal cells
were negative in endometrium from postmenopausal
women and proliferative phase endometrium (Fig 2A and
2B, Figure 3F and 4E). IL11 immunostaining was signifi-
cantly higher in epithelial tumour cells from Grades 1 and
3 but not Grade 2 tissue compared to endometrial epithe-
lial cells from proliferative phase women (p < 0.05 in G1
and p < 0.001 in G3, Fig 1A) but was higher only in Grade
1 compared to postmenopausal women. There was no
significant difference in IL11 staining in epithelial cancer
cells between the tumour grades (Fig 2A). IL11Rα stain-
ing was higher in epithelial tumour cells in Grade 1 and 2
but not Grade 3 compared to endometrial epithelial cells
from control postmenopausal women (p < 0.05, Fig 2B).
Similar to IL11, there was no significant difference in
IL11Rα staining in epithelial cancer cells between the
tumour grades (Fig 2B).
IL11 staining was also present in vascular endothelial
and smooth muscle cells in Grade 3 tumours (Fig 3D-E).
Similarly, positive staining for IL11Rα was seen in vascu-
lar smooth muscle and endothelial cells in Grade 3
tumours but not in Grades 1 and 2 (Fig 4D). No staining
for IL11 and IL11Rα was seen in vascular endothelial and
smooth muscle cells in postmenopausal endometrium or
proliferative phase endometrium (data not shown).
Intense staining for IL11 was seen in subpopulations of
leukocytes infiltrating the cancer glands in four of the six
Grade 3 tumours (Fig 3E). Secretory phase endometrium
served as positive controls for IL11 and IL11Rα and dem-
onstrated positive IL11 and IL11Rα staining in glandular
epithelium as previously reported (Fig 3G and Fig 4F)
[12]. No immunostaining was detected in the IL11 and
IL11Rα negative controls (Fig 3H and 4G).
Immunolocalisation of pSTAT3 and SOCS3 in endometrial 
cancer tissue and endometrium from post-menopausal 
women
Staining for pSTAT3 was detected in epithelial and
stromal compartments in the endometrial carcinomas
and postmenopausal endometrium (Fig 5A-C and 5G).
pSTAT3 immunostaining was low in the postmenopausal
epithelium and proliferative phase. pSTAT3 was signifi-
cantly increased in the cancer epithelium in Grades 1 and
2 compared to proliferative phase epithelium (Fig 2C).
pSTAT3 staining in the tumour stroma was low to mod-
erate but was minimal in the endometrium from post-
menopaual women (Fig 5A-C and 5G). While there was
Figure 1 IL11 is present in uterine washings in women with endo-
metrial cancer. Uterine washings were collected from women with 
Grade 1 (N = 4), Grade 2 (N = 5) and Grade 3 (N = 6) cancer and IL11 
was measured by ELISA. Individual data shown for each parameter. 
Data represented as mean ± SEM. ND-not detectable * represents P < 
0.05 compared to postmenopausal control.
NDYap et al. Reproductive Biology and Endocrinology 2010, 8:63
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an increase in pSTAT3 immunostaining intensity in the
Grades 1 and 2 compared to postmenopausal epithelium,
it did not reach significance (Fig 5C). There were no sta-
tistical differences in tumour stroma between cancer
grades and also between each cancer grade and post-
menopausal endometrium (data not shown). SOCS3 loc-
alised primarily to the endometrial cancer epithelium in
all grades of carcinomas (Fig 5D-F). There was minimal
Figure 2 Immunohistochemical localisation scores in endometrial cancer and postmenopausal endometrium. Immunostaining of IL11 (A), 
IL11Rα (B), pSTAT3 (C) and SOCS3 (D) in tumor epithelial cells in endometrial carcinoma. Relative staining intensities are represented as 0 (no staining) 
to 3 (maximal staining). Post-menopausal women were controls (n = 4) while endometrial carcinomas were from Grades 1-3 (Grade 1: n = 5, Grade 2: 
n = 5, Grade 3: n = 6). Individual data shown for each parameter. Results presented as mean. Proliferative = proliferative phase of the menstrual cycle. 
* P < 0.05, ** P < 0.001 compared to postmenopausal control.Yap et al. Reproductive Biology and Endocrinology 2010, 8:63
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staining for SOCS3 in endometrial epithelial cells from
the postmenopausal women (Fig 5H). SOCS3 in prolifer-
ative phase epithelium was significantly higher compared
to epithelium in post-menopausal controls and all
Tumour Grades (Fig 2D). However, there were no signifi-
cant difference in SOCS3 staining in the epithelial
tumour cells between tumour grades (Fig 2D).
IL11 regulation of pSTAT3 and SOCS3 in human 
endometrial cancer cell lines
Overall, all the human endometrial cancer cell lines
(ECC-1: 5 pg/106 cells, HEC-1A: 3 pg/106 cells, Ishikawa
cells: 6 pg/106 cells) and the endometrial epithelial cell
line HES, secreted very low levels of IL11 under serum
free conditions. The cells were subsequently cultured in
serum free conditions to examine the effect of IL11 on
pSTAT3/STAT3 and SOCS3 protein abundance.
The effect of IL-11 on pSTAT3 and STAT3 in human
endometrial epithelial cancer cell lines was examined by
Western blot (Fig 6A top). Addition of IL-11 to ECC-1
cells weakly stimulated pSTAT3 at 100 pg/ml while there
was no activation with all other concentrations. By con-
trast, IL11 stimulated pSTAT3 from 1-10 ng/ml in HEC-
1A and 1 ng/ml in Ishikawa endometrial carcinoma cells
respectively compared to diluent control treated cells (Fig
6B and 6C). STAT3 protein abundance was not affected
at any IL11 concentration tested in all carcinoma cell
lines (Fig. 6A).
To determine the effect of IL-11 on SOCS3 protein
abundance, endometrial carcinoma and non-carcinoma
(HES) cells were treated with IL-11 for 4 hours and
SOCS3 abundance examined at 0 (before treatment) and
4 hrs as previously described [9]. SOCS3 protein abun-
dance in ECC-1 cells did not change with addition of IL11
(Fig. 7A). In HEC-1A (Fig. 7B) and Ishikawa carcinoma
cells (Fig. 7C), there was an upregulation of SOCS3 pro-
tein following the addition of 100 ng/ml IL11 compared
to respective controls. In non-carcinoma HES cells,
SOCS3 protein increased after addition of IL11 from 1-
500 ng/ml (Fig. 7D). Addition of IL11 antagonist with 100
ng/ml IL11 reduced SOCS3 protein compared to controls
(Fig. 7D).
Discussion
This study was the first to show that IL11 protein was
increased in uterine fluid and endometrial tumour epi-
thelial cells in women with Grade 1 endometrial carci-
noma compared to postmenopausal women. It further
demonstrated that IL11's main endometrial signalling
Figure 3 IL11 immunolocalisation in endometrial cancer and 
postmenopausal endometrium. Photomicrographs representing 
IL11 staining in endometrial cancers of (A) Tumour Grade 1, (B) Tumour 
Grade 2, (C-E) Tumour Grade 3, (F) postmenopausal endometrium, (G) 
secretory phase endometrium and (H) negative control. Positive stain-
ing shown as brown pigment with blue nuclear counterstain. Scale 
bars = 50 μm. (T) cancer epithelial cells, (GE) glandular epithelium, (EC) 
vascular endothelial cells, (SMC) smooth muscle cells and (S) stromal 
cells.
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Figure 4 IL11Rα immunolocalisation in endometrial cancer and 
postmenopausal endometrium. Photomicrographs representing 
IL11Rα staining in endometrial cancer of (A) Tumour Grade 1, (B) Tu-
mour Grade 2, (C-D) Tumour Grade 3, (E) postmenopausal endometri-
um, (F) secretory phase endometrium and (G) negative control. 
Positive staining shown as brown pigment with blue nuclear counter-
stain. Scale bars = 50 μm. (T) tumour epithelial cells, (GE) glandular ep-
ithelium, (EC) vascular endothelial cells, (SMC) smooth muscle cells and 
(S) stromal cells
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molecules, pSTAT3 and SOCS3, were produced by endo-
metrial cancer cells. IL11 was shown to signal via
pSTAT3 and SOCS3 in human endometrial cancer cell
lines.
Endometrial glandular epithelial products are primarily
secreted apically into the uterine lumen therefore we
investigated the levels of IL11 in uterine flushings. In
agreement with our study, a previous study has suggested
that factors present in uterine washings may confirm the
presence of endometrial cancer [23]. IL11 levels in uter-
ine washings were very high (10-100 fold) in a cohort of
women with Grade 3 cancers compared to the other
tumour grades and controls. As endometrial cancer pro-
gresses, the epithelial cancer cells lose their polarity. Our
study suggests that non-polarised endometrial cancer
epithelial cells may also secrete products into the uterine
lumen. It is also possible that IL11 may be secreted by the
cancer associated leukocytes into the uterine lumen in
the Grade 3 tumours thereby contributing to the IL11 lev-
els found in the lavage fluid.
Previous studies have shown that in cycling endome-
trium, IL11 and IL11Rα predominantly localise to human
endometrial glandular epithelium and decidualized
human endometrial stromal cells [12,28]. Endometrial
IL11 protein production alters with cyclical variation; in
the glandular epithelium it is low in the proliferative
phase of the menstrual cycle and increases in the mid-late
secretory phase [12]. However, since endometrial cancer
affects predominantly post-menopausal women, we com-
pared the levels of IL11, IL11Rα, pSTAT3 and SOCS3 in
endometrial cancer tissue to endometrial tissue from
post-menopausal.
In agreement with our study, IL11 localised predomi-
nantly to cancer epithelial cells in a recent report [13].
IL11 mRNA was reported to be higher in endometrial
cancer tissue compared to endometrial tissue from prolif-
erative phase tissue, while differences in the level of IL11
protein between the groups was not reported [13]. Our
data demonstrated that IL11 protein was significantly ele-
vated specifically in endometrial epithelial tumor cells
early in the Grade 1 tumours compared to postmeno-
pausal controls reflecting the data in uterine washings.
This suggests that IL11 levels in uterine washings may be
useful as an endometrial cancer marker.
IL11Rα protein was upregulated in endometrial epithe-
lial tumour cells compared to endometrial epithelium
from postmenopausal women. Strong staining for both
IL11 and IL11Rα was identified in tumour vascular
endothelial and smooth muscle cells as recently reported
[13].
Figure 5 pSTAT3 and SOCS3 localisation in endometrial cancer 
and postmenopausal endometrium. Photomicrographs represent-
ing pSTAT3 (A-C) and SOCS3 (D-F) in endometrial cancers. A and D are 
Tumour Grade 1; B and E are Tumour Grade 2; C and F are Tumour 
Grade 3; G and H are control postmenopausal endometrium (G shows 
pSTAT3 and H shows SOCS3). I and J are positive controls for pSTAT3 
and SOCS3 respectively showing secretory phase endometrium (insets 
are negative controls for each). Positive staining shown as brown pig-
ment with blue nuclear counterstain. Negative controls (IgG isotype 
controls) are shown as insets for pSTAT (G) and SOCS3 (H). Scale bars = 
50 μm. (T) tumour epithelial cells, (GE) glandular epithelium and (S) 
stromal cells
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Figure 6 Effect of IL-11 on STAT3 phosphorylation in human en-
dometrial cancer cell lines. Cells were cultured with IL-11 (1-500 ng/
ml) for 15 min. A: ECC-1 cells. B: HEC-1A cells. C: Ishikawa cells. Cell 
lysates (30 μg protein) were electrophoresed by SDS-PAGE and immu-
noblotted with anti-p(Tyr705)STAT3 (top panel) or anti-STAT3 (bottom 
panel) followed by HRP-conjugated rabbit antiserum and visualized by 
chemiluminescence. cont = control
ECC-1
STAT3 
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IL11 localised to leukocytes only in the advanced Grade
3 tumours and not in control postmenopausal endome-
trium. Numerous studies report that tumour associated
macrophages promote angiogenesis and correlate with
poor prognosis [29]. In endometrial cancer, tumour asso-
ciated macrophages are associated with vascular space
invasion and myometrial invasion [30]. It is likely that
factors produced by tumour associated leukocytes con-
tribute to tumourigenesis.
In agreement with the present study, IL11 is signifi-
cantly upregulated in several non-endometrial cancers.
IL11 and IL11Rα transcript levels are linked to breast
cancer prognosis - breast tumours with a poor prognostic
index show a high level of IL11 [31]. Similarly, IL11 and
IL11Rα protein are highly expressed in human colorectal
adenocarcinoma and IL11Rα levels correlate with clinico-
pathological factors [32]. IL11 is also increased in gastric
cancer [14]. Overall, these studies indicate that IL11 may
play a role in tumour formation.
Tumour development and progression depends on cell
adherence to extracellular matrix, proliferation, migra-
tion and invasion of tumour cells followed by their metas-
tasis into other tissues and on escaping immune
detection and destruction. Our previous studies show
that IL11 increases the adhesion of human endometrial
epithelial cells to various extracellular matrix molecules
and to human trophoblast, at least in part by regulating
adhesion molecule mRNA expression and protein pro-
duction [10]. Endometrial extracellular matrix molecules
appear to be targets of IL11 actions in mouse implanta-
tion sites [33]. IL11 also regulates the migration and inva-
sion of human trophoblast, a process that is highly
regulated but nevertheless has many similarities with
tumour cell invasion [21,22]. Furthermore, IL11 and
IL11Rα expression correlate with invasion and prolifera-
tion in human gastric and colorectal tumours [34,35].
It remains to be determined whether IL11 similarly reg-
ulates tumour cell adhesion, migration and invasion in
endometrial cancers. Angiogenesis is also a key determi-
nant of tumour formation [36] and hence the localization
of IL11 and IL11Rα to vascular smooth muscle and
endothelial cells in the present study suggest a potential
role in angiogenesis. In the stomach, IL11 increases
angiogenesis accelerating ulcer healing in mice [37].
IL11Rα protein is a proposed candidate target for both
human osteosarcoma and also bone metastasis [16]. Fur-
thermore IL11 alters the expression of proliferative and
cytoprotective genes and promotes pre-tumorigenic cel-
l u l a r  c h a n g e s  i n  m i c e  i n  v i v o  s u g g e s t i n g  t h a t  I L 1 1  i s
involved early in tumourigenesis [14]. pSTAT3 staining
intensity tended to be higher in the tumour epithelial
cells compared to endometrium from postmenopausal
women although it did not reach significance likely due to
the large variability in staining intensity within the con-
trol group of women. By contrast, pSTAT3 intensity was
higher in Grade 1 and 2 tumours compared to endome-
trial glandular epithelium from proliferative phase tissue.
This suggests that caution must be used when comparing
endometrial cancer proteins with proliferative phase
endometrium.
Overall, SOCS3 imunostaining intensity was low in epi-
thelium from postmenopausal women and all tissues
from the cancer patients. There was higher SOCS3 stain-
ing in endometrial glandular epithelium from prolifera-
tive phase endometrium compared to all other groups.
This suggests that SOCS3 has different functions in
cycling endometrium compared to endometrium from
postmenopausal women and endometrial cancer.
IL11 increases pSTAT3 and SOCS3 protein in differen-
tiating human endometrial stromal cells [38]. STAT3
which is phosphorylated by numerous cytokines, growth
factors and oncogenetic proteins, is constitutively phos-
phorylated in many human cancer tissues and cell lines
[18]. STAT3 target genes are implicated in multiple steps
of tumour metastasis including cell invasion, survival,
renewal and angiogenesis and thus pSTAT3 can be
Figure 7 Effect of IL-11 on SOCS3 in human endometrial cancer 
and non-cancer cell lines. Cells were cultured with IL-11 (1-500 ng/
ml) for 4 hours. A: ECC-1 cells. B: HEC-1A cells. C: Ishikawa cells. D: HES 
cells (non-cancer endometrial epithelial cell line). Cell lysates (30 μg 
protein) were electrophoresed by SDS-PAGE and immunoblotted with 
anti-SOCS3 (top panel) or anti-b-actin (loading control; bottom panel) 
followed by HRP-conjugated rabbit antiserum and visualized by 
chemiluminescence. cont = control IL11 ant = IL11 antagonist
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regarded as a pivotal regulator of tumour metastasis [18].
It was of interest in the present study to investigate
whether specifically IL11 regulated pSTAT3 and SOCS3
in cancer cells as both have been shown to be involved in
numerous tumours. The intense staining identified for
pSTAT3 in endometrial cancer associated epithelium and
stroma, suggests a role in both stromal and epithelial
compartments for pSTAT3 in endometrial tumour for-
mation. IL11 is predominantly restricted to cancer epi-
thelium and not cancer associated stromal fibroblasts,
suggesting that in the cancer stroma, factors other than
IL11 regulate pSTAT3. Whether IL11 alone activates
STAT3 phosphorylation in endometrial cancer cells
remains to be elucidated.
Several studies have shown that SOCS proteins includ-
ing SOCS3 are expressed in tumours including head and
neck cancer [39,40], gastric carcinoma [41], chronic
myeloid leukemia [42], melanoma [43] and prostate can-
cer [44,45]. SOCS3 is upregulated in prostate cancer and
inhibits the induction of apoptosis by cAMP [44].
In the present study SOCS3 staining intensity was
absent or very minimal in tumour epithelial cells in the
Grade 3 cancer specimens perhaps similarly indicating a
reduced sensitivity to SOCS3 in endometrial cancers
although this remains to be determined. In normal breast
epithelial cells SOCS3 is induced, while in several breast
cancer cell lines SOCS3 is weakly activated. In breast
t u m o u r  c e l l s ,  i t  h a s  b e e n  p o s t u l a t e d  t h a t  t h e  I F N γ
induced anti-proliferative effects are reduced due to a
lower sensitivity to SOCS3 induction [19]. Our in vitro
studies identified that IL11 (from 1 ng/ml) stimulated
SOCS3 protein abundance in non-carcinoma HES cells.
By contrast IL11 weakly stimulated SOCS3 protein at 100
ng/ml in the carcinoma HEC-1A and Ishikawa cells possi-
bly suggesting reduced sensitivity in endometrial cancer
cells. The mechanisms by which this may occur are
unknown. The consequences of this reduced sensitivity
could be that IL11 signalling is unregulated in endome-
trial cancer cells. This however this remains to be deter-
mined and the functional significance remains to be
elucidated.
Conclusions
Our study suggests that IL11 in uterine washings may be
useful as an early marker of endometrial cancer. It is also
the first study to demonstrate that IL11 protein is upregu-
lated in Grade 1 endometrial cancers compared to post-
menopausal endometrial epithelium and suggests that
IL11 signalling is active in endometrial cancer cells. The
present study suggests that IL11, along with its specific
receptor and downstream signalling molecules pSTAT3
and SOCS3, are likely to play a complex role in the pro-
gression of endometrial carcinoma. Functional studies
are required to elucidate the role of IL11 in tumourigene-
sis and determine its potential as a prognostic marker and
therapeutic target for endometrial cancer. Large scale
studies are required to determine whether IL11 in uterine
washings may be useful as a diagnostic marker for endo-
metrial cancer.
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